New cancer drug DB-1317 enters first human tests for advanced tumors

NCT ID NCT07141706

Recruiting now Disease control Sponsor: DualityBio Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 32 times

Summary

This early-phase study tests a new drug called DB-1317 in about 233 adults with advanced solid tumors that have worsened after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants will receive the drug intravenously and be monitored for side effects and response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

AUS01-0
RECRUITING

Randwick, New South Wales, 2031, Australia
Site USA06-0
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
USA01
RECRUITING

Fairfax, Virginia, 22031, United States
USA02-0
RECRUITING

Houston, Texas, 77030, United States
USA03-0
RECRUITING

San Antonio, Texas, 78229, United States
USA04-0
RECRUITING

Los Angeles, California, 90025, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED/METASTATIC SOLID TUMORS